Lisa Cook sues Trump over firing attempt, emergency hearing set
Medpace Holdings (NASDAQ:MEDP), based in Cincinnati, is a company involved in commercial physical and biological research services. With a market capitalization of $9.9 billion, the company has demonstrated strong performance with 11.8% revenue growth over the last twelve months and maintains a healthy P/E ratio of 25. InvestingPro analysis reveals 8 additional key insights about MEDP’s performance and valuation, available in the comprehensive Pro Research Report, which provides deep-dive analysis of 1,400+ top US stocks. With a market capitalization of $9.9 billion, the company has demonstrated strong performance with 11.8% revenue growth over the last twelve months and maintains a healthy P/E ratio of 25. InvestingPro analysis reveals 8 additional key insights about MEDP’s performance and valuation, available in the comprehensive Pro Research Report, which provides deep-dive analysis of 1,400+ top US stocks.
Medpace Holdings, based in Cincinnati, is a company involved in commercial physical and biological research services.
In other recent news, Medpace Holdings, Inc. reported fourth-quarter earnings that exceeded analyst expectations. The company posted an adjusted earnings per share of $3.67, surpassing the consensus estimate of $2.94. Revenue for the quarter was $536.6 million, slightly above the projected $534.86 million and marking a 7.7% increase from the same quarter last year. However, Medpace’s 2025 revenue guidance of $2.11 billion to $2.21 billion fell short of the $2.238 billion analysts anticipated, causing concern among investors. This outlook suggests a growth range of 0.0% to 4.8% over the 2024 revenue of $2.109 billion.
CEO August Troendle noted a cautious approach to the 2025 forecast due to economic uncertainties. The company reported net new business awards of $529.7 million for the fourth quarter, a 13.8% decrease year-over-year, with a net book-to-bill ratio of 0.99x. Medpace’s backlog increased by 3.2% to $2.90 billion as of December 31, 2024. Additionally, the board approved a $600 million increase to its stock repurchase program, with 527,160 shares repurchased at an average price of $330.43 per share during the quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.